Immatics at the ASCO Annual Meeting 2018 (June 1-5) in Chicago, IL

| News

Immatics at ASCO Annual Meeting, June 1-5 in Chicago! If you're there take the chance to discuss cancer care treatment and partnering options with present Senior Management and other experts from Immatics. 


Don't miss out on results from the GAPVAC clinical trial:

The oral presentation "GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma" (Abstract #2000)by Lead Investigator Prof. Dr. Wolfgang Wick (University Hospital Heidelberg, Germany) will take place on June 1st during the Central Nervous System Tumors session (starting 2:45 pm CDT, S102).
GAPVAC is an EU-funded consortium with the goal to establish an actively personalized vaccination approach in glioma treatment. The consortium integrates thirteen partners from industry and academia and is led by the biotech companies Immatics and BioNTech.
Also learn about the ACTolog® concept and clinical trial overcoming limitations of benefit for solid tumor patients:

The poster presentation "Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers" (Poster Board #317b, Abstract #TPS3106) by Dr Apostolia Maria Tsimberidou and colleagues from MD Anderson Cancer Center and Immatics will take place on June 4th during the Developmental Therapeutics—Immunotherapy Poster Session (starting 8:00 am CDT, Hall A).

IMA101 is a personalized, multi-targeted investigational immunotherapy for the treatment of multiple solid tumors, including but not limited to ovarian cancer, gastric cancer, esophageal cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer. The single-center study is open for enrollment at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Further information on ASCO here.

Press Contact

Anja Heuer

Corporate Communications,
Immatics Biotechnologies GmbH

+49 89 540 415 606

Go back

We use cookies to ensure that we give you the best experience on our website.